Leishmania: Leishmaniasis — Sandfly-Borne Parasite and Three Forms of Disease

Deep-Dive Articles

Leishmaniasis is caused by Leishmania protozoa transmitted by sandfly bites and affects 12 million people across 98 countries. It manifests in three forms: cutaneous (skin ulcers that heal slowly over months to years), mucocutaneous (disfiguring destruction of the nose, mouth, and throat), and visceral (kala-azar — the deadliest form, attacking the spleen, liver, and bone marrow, fatal if untreated). Despite its enormous global burden, leishmaniasis remains one of the most neglected of all tropical diseases, primarily striking the world's poorest populations in Asia, Africa, Latin America, and the Mediterranean basin.

Table of Contents

1. Deep-Dive Articles
2. What Leishmania Is
3. How Sandflies Transmit It
4. The Three Clinical Forms
5. Cutaneous Leishmaniasis
6. Mucocutaneous Leishmaniasis
7. Visceral Leishmaniasis (Kala-Azar)
8. Diagnosis
9. Treatment
10. Key Research Papers
11. Featured Videos

1. What Leishmania Is

Leishmania is a genus of single-celled protozoan parasites belonging to the order Kinetoplastida. More than 20 species are capable of infecting humans, each causing a somewhat different pattern of disease and occurring in a different geographic range. Like Plasmodium (the malaria parasite), Leishmania is an intracellular organism — it lives and reproduces inside the cells of its host, specifically inside macrophages, the very immune cells that are supposed to destroy invading pathogens. This ability to hijack and survive within the cells tasked with killing it is central to the parasite's persistence and the difficulty of treating the disease it causes.

Leishmania exists in two main forms during its life cycle. In the sandfly vector it lives as an elongated, flagellated form called a promastigote, which is mobile and adapted for survival in the insect gut. Once injected into a mammalian host during a sandfly bite, the parasite sheds its flagellum and transforms into a small, rounded, non-motile form called an amastigote. It is the amastigote that survives inside macrophages and is responsible for all of the clinical disease in humans.

The World Health Organization estimates that 700,000 to 1 million new cases of leishmaniasis occur each year, with the visceral form alone responsible for an estimated 20,000–30,000 deaths annually. Roughly 90% of new visceral cases occur in just six countries: Bangladesh, Brazil, Ethiopia, India, South Sudan, and Sudan. The disease is classified as a neglected tropical disease, meaning it affects primarily low-income populations in resource-limited settings and has historically received far less research and drug-development attention than its burden warrants.

2. How Sandflies Transmit It

The vectors of leishmaniasis are small, blood-sucking flies in the genus Phlebotomus (in the Old World — Europe, Asia, and Africa) and Lutzomyia (in the New World — the Americas). These are tiny insects, roughly one-third the size of a mosquito, with a characteristic hairy appearance and a jerky, hopping flight pattern. They breed in soil rich in organic matter — leaf litter, cracks in walls, animal burrows — and feed primarily at dawn, dusk, and during the night.

Transmission occurs when an infected female sandfly takes a blood meal. As she feeds, she deposits promastigotes into the skin. The promastigotes are rapidly engulfed by the body's macrophages, which normally patrol the skin and engulf foreign material. Rather than being destroyed, the parasites transform into amastigotes and begin to multiply inside the macrophage, eventually bursting the cell and infecting new ones. A sandfly that feeds on an infected host ingests amastigote-laden macrophages, and the cycle continues as the parasites transform back into promastigotes in the fly's gut and migrate forward to the salivary glands, ready to infect the fly's next host.

Beyond the sandfly bite, Leishmania can also be transmitted in rare circumstances through blood transfusion, contaminated needles among people who inject drugs, and congenitally from a pregnant woman to her unborn child. In areas where the disease is endemic in domestic dogs — a major reservoir in parts of southern Europe and Latin America — the infection circulates among dogs and sandflies, with humans as incidental hosts. Control programs in some settings have therefore combined human treatment with control of the canine reservoir and insecticide spraying against sandfly populations.

3. The Three Clinical Forms

The species of Leishmania that infects a person, together with the immune status of the host, determines which of the three broad clinical forms of leishmaniasis develops. This distinction matters enormously, because the three forms differ profoundly in their severity, location, treatment, and risk of lasting harm:

• Cutaneous leishmaniasis (CL) — by far the most common form, accounting for the majority of all cases worldwide. The parasite stays localized in the skin, producing characteristic ulcers at the site of the sandfly bite. The disease is self-limiting in most cases but can take months to years to heal and leaves permanent scars.
• Mucocutaneous leishmaniasis (MCL) — a much rarer and more severe form, occurring primarily in Latin America and caused mainly by L. braziliensis and related species. Parasites from an initial skin infection spread to the mucous membranes of the nose, mouth, and throat, causing progressive, disfiguring destruction of the nasal septum, palate, and pharynx. Unlike CL, MCL does not resolve on its own and can be fatal if the airway is compromised.
• Visceral leishmaniasis (VL) — kala-azar — the most dangerous form. Parasites disseminate through the bloodstream to invade macrophages throughout the body, particularly in the spleen, liver, and bone marrow. Without treatment, visceral leishmaniasis is almost always fatal. The name "kala-azar" comes from the Hindi for "black fever," a reference to the skin darkening observed in severe cases.

It is worth noting that some species of Leishmania primarily cause one form or another — for example, L. donovani causes visceral disease in South Asia and East Africa, while L. major causes cutaneous disease in the Middle East and Central Asia — but the clinical spectrum is not entirely rigid, and the host's immune response shapes the outcome as much as the species does.

4. Cutaneous Leishmaniasis

Cutaneous leishmaniasis is the most common form of the disease, responsible for an estimated 600,000–1 million new cases annually. It is endemic in large parts of the Middle East, Central Asia, the Indian subcontinent, Sub-Saharan Africa, and Latin America, with over 80% of cases occurring in just ten countries: Afghanistan, Algeria, Brazil, Colombia, Iran, Iraq, Morocco, Pakistan, Peru, and Syria. Conflict-driven population displacement has dramatically expanded its geographic reach in recent decades.

The typical lesion begins as a small, firm papule (bump) at the site of the sandfly bite, usually appearing one to several weeks after the bite. Over weeks to months the papule enlarges and the center breaks down to form a characteristic painless ulcer with raised, indurated (hardened) edges — sometimes described as having a "volcano crater" appearance. The ulcer may enlarge to several centimeters in diameter and can be accompanied by satellite lesions or regional lymph node swelling. Secondary bacterial infection is common and can obscure the underlying diagnosis.

The ulcer eventually heals spontaneously in most patients, but this can take months to years depending on the infecting species and the patient's immune response. Healing leaves a permanent, often disfiguring scar. In patients with immune deficiencies (including untreated HIV infection), cutaneous leishmaniasis can become disseminated or fail to heal at all. Because scars are permanent and can occur on the face, the disease carries a significant psychological and social burden, particularly among women and girls in societies where such scarring is heavily stigmatized.

Treatment of CL varies by species, region, and severity. Localized lesions caused by species that do not spread to mucous membranes may be managed with intralesional injections of antimonial drugs, cryotherapy, or topical therapy. More widespread disease, disease caused by species at risk of mucosal spread (particularly L. braziliensis), or disease in immunocompromised patients typically requires systemic treatment with liposomal amphotericin B or other agents.

5. Mucocutaneous Leishmaniasis

Mucocutaneous leishmaniasis is the least common but among the most destructive of the three forms. It occurs predominantly in Latin America and is caused mainly by Leishmania (Viannia) braziliensis and closely related species. It represents a complication of cutaneous infection in which parasites metastasize — via lymphatic or blood-borne spread — from the skin to the mucous membranes, typically of the nose, mouth, palate, and pharynx.

Mucosal disease often appears months to years after the initial cutaneous ulcer has healed, making the connection to leishmaniasis easy to miss. The earliest symptoms are typically nasal — stuffiness, discharge, and nosebleeds — progressing to destruction of the nasal septum (producing the characteristic "tapir nose" deformity when the nose collapses), spread to the lips, gums, palate, tonsils, and larynx. In advanced cases, massive destruction of the midface can render eating and breathing difficult, and laryngeal involvement can lead to airway obstruction. Unlike cutaneous disease, mucocutaneous leishmaniasis does not heal spontaneously; it is uniformly progressive if untreated.

The diagnosis of MCL can be elusive because the parasite burden in mucosal lesions is typically low, making microscopy and culture insensitive. Diagnosis usually combines clinical history (past travel to or residence in an endemic area, history of a cutaneous ulcer), serology (anti-Leishmania antibody titers are often strongly positive), and PCR on biopsy tissue. Treatment requires systemic antileishmanial drugs; historically the pentavalent antimonials were the mainstay, but liposomal amphotericin B is increasingly used given its superior tolerability.

6. Visceral Leishmaniasis (Kala-Azar)

Visceral leishmaniasis is the most severe form of the disease and is almost universally fatal without treatment. It is caused primarily by L. donovani (in South Asia and East Africa) and L. infantum/L. chagasi (in the Mediterranean basin and Latin America). After a bite from an infected sandfly, the parasites disseminate through the bloodstream and multiply inside macrophages throughout the reticuloendothelial system.

The incubation period ranges from months to years after the infective bite. Classical kala-azar presents with:

• Prolonged irregular fever — characteristically spiking twice daily, but highly variable.
• Massive splenomegaly — the spleen, engorged with parasitized macrophages, can become extremely enlarged, sometimes extending to the pelvis. It is often the most prominent physical finding.
• Hepatomegaly — liver enlargement, though less dramatic than splenic enlargement.
• Progressive weight loss and wasting — the combination of poor appetite, metabolic derangement, and systemic inflammation leads to profound cachexia over months.
• Pancytopenia — destruction of bone marrow function leads to anemia (causing pallor and fatigue), neutropenia (increasing susceptibility to secondary infections), and thrombocytopenia (causing bleeding). It is often secondary infections — pneumonia, tuberculosis, or sepsis — that ultimately kill untreated patients.
• Hypergammaglobulinemia and hypoalbuminemia — abnormal immune activation drives excess antibody production while albumin levels fall, sometimes leading to edema.
• Skin darkening (hyperpigmentation) — especially on the face, hands, and abdomen, giving rise to the name kala-azar ("black fever" in Hindi).

Post-kala-azar dermal leishmaniasis (PKDL) is an important late complication occurring in some patients months to years after apparently successful treatment of visceral leishmaniasis, particularly in South Asia. It presents as a skin rash — macular, papular, or nodular — that can last for months to years and serves as a reservoir for transmission, since the skin lesions contain viable parasites that can infect sandflies.

Visceral leishmaniasis has a particularly dangerous interaction with HIV co-infection. HIV weakens exactly the macrophage-driven immune responses needed to control Leishmania, and visceral leishmaniasis in an HIV-infected person is a rapidly progressing, treatment-resistant, and frequently relapsing disease that has become a significant problem in parts of southern Europe, Brazil, and East Africa where both infections are common.

7. Diagnosis

The diagnosis of leishmaniasis combines clinical suspicion with laboratory confirmation, and the approach differs somewhat across the three forms:

• For cutaneous leishmaniasis: Skin slit smear or biopsy of the ulcer edge provides material for direct microscopy (looking for amastigotes inside macrophages), culture (growing the parasite in specialized media), and PCR (detecting Leishmania DNA). PCR is the most sensitive technique and can also identify the species, which guides treatment choice. Serology is not reliable for CL because antibody responses are often weak or absent.
• For mucocutaneous leishmaniasis: Mucosal biopsy for PCR, combined with serology (antibody titers are typically high in MCL) and clinical history. Microscopy and culture are less sensitive because the parasite burden in mucosal tissue is low.
• For visceral leishmaniasis: The most specific diagnostic test has traditionally been aspiration of the spleen or bone marrow for smear and culture, but splenic aspiration carries bleeding risk. A major advance has been the development of rapid diagnostic tests (RDTs) based on detection of antibodies against the recombinant antigen rK39 — a simple dipstick test that is highly sensitive and specific for VL caused by L. donovani (though less accurate for VL caused by L. infantum). PCR on peripheral blood is highly sensitive and increasingly used where available. Blood tests typically show anemia, low white cell and platelet counts, elevated liver enzymes, low albumin, and very high globulin levels.

Because leishmaniasis occurs primarily in resource-limited settings, diagnostic algorithms must often be adapted to what is actually available. In highly endemic areas, a compatible clinical picture plus a positive rK39 RDT is sufficient to start treatment for visceral leishmaniasis without further invasive testing.

8. Treatment

The treatment of leishmaniasis depends on the clinical form, the infecting Leishmania species, the geographic region (because drug resistance and efficacy vary), and the patient's immune status. No single regimen is appropriate for all forms in all settings, and drug toxicity is a significant concern with all antileishmanial agents. The information here reflects published medical literature and clinical guidance; specific dosing must be directed by a specialist with expertise in tropical medicine.

• Liposomal amphotericin B (AmBisome) is now the first-line treatment for visceral leishmaniasis in many settings, including the United States, Europe, and increasingly South Asia. A landmark clinical trial in India demonstrated that a single infusion of liposomal amphotericin B cured 95.7% of patients, dramatically simplifying treatment. Compared with conventional amphotericin B, the liposomal formulation is far better tolerated, with markedly less kidney toxicity. Its main limitation is cost, which restricts access in low-income settings.
• Miltefosine is the first and, for many years, the only oral drug effective against visceral leishmaniasis. It represented a major advance for treatment in resource-limited settings where intravenous therapy is impractical. A pivotal NEJM trial showed cure rates over 90% in Indian VL. Miltefosine is also used for cutaneous and mucocutaneous leishmaniasis, particularly in the Americas. Its main limitations are teratogenicity (it cannot be used in pregnancy) and the emergence of treatment-resistant parasites in South Asia.
• Pentavalent antimonials (meglumine antimoniate and sodium stibogluconate) were for decades the standard treatment for all forms of leishmaniasis and remain widely used in many regions, particularly for cutaneous disease. However, L. donovani in Bihar state, India, has developed high-level resistance to antimonials, making them unreliable there for visceral disease.
• Paromomycin (an aminoglycoside antibiotic with antiparasitic activity) has demonstrated efficacy against visceral leishmaniasis in East Africa and South Asia and is used as part of combination regimens to shorten treatment duration and reduce the risk of resistance developing to any single agent.
• Combination therapy — using two drugs together (for example, liposomal amphotericin B plus miltefosine, or miltefosine plus paromomycin) — is increasingly recommended to maximize cure rates and reduce the risk of drug resistance emerging, analogous to combination approaches used in HIV and tuberculosis.

For cutaneous leishmaniasis, local treatments (intralesional antimonials, cryotherapy, thermotherapy) are options for localized, small lesions caused by species that do not carry mucosal risk. Systemic treatment is required for mucocutaneous disease and for CL in immunocompromised patients or when caused by species with mucosal potential.

Key Research Papers

Peer-reviewed studies and authoritative reviews on Leishmania biology, disease burden, diagnosis, and treatment across all three clinical forms. DOI links open the full citation.

1. Alvar J, Vélez ID, Bern C, et al. Leishmaniasis Worldwide and Global Estimates of Its Incidence. PLoS ONE. 2012;7(5):e35671.
2. Chappuis F, Sundar S, Hailu A, et al. Visceral Leishmaniasis: What Are the Needs for Diagnosis, Treatment and Control? Nature Reviews Microbiology. 2007;5(11 Suppl):S7–S16.
3. Reithinger R, Dujardin J-C, Louzir H, et al. Cutaneous Leishmaniasis. The Lancet Infectious Diseases. 2007;7(9):581–596.
4. Sundar S, Jha TK, Thakur CP, et al. Oral Miltefosine for Indian Visceral Leishmaniasis. New England Journal of Medicine. 2002;347(22):1739–1746.
5. Sundar S, Chakravarty J, Agarwal D, et al. Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India. New England Journal of Medicine. 2010;362(6):504–512.

Live PubMed Searches

Each link opens a live PubMed query so results stay current as new papers are indexed.

1. Leishmaniasis review
2. Visceral leishmaniasis / kala-azar treatment
3. Cutaneous leishmaniasis diagnosis and treatment
4. Mucocutaneous leishmaniasis
5. Liposomal amphotericin B for VL
6. Miltefosine clinical trials
7. Sandfly transmission of Leishmania
8. Leishmaniasis and HIV co-infection

Back to Table of Contents

Connections

• Leishmania: Symptoms Hub
• Cutaneous & Mucosal Leishmaniasis
• Visceral Leishmaniasis (Kala-Azar)
• Diagnosis: Microscopy & PCR
• Leishmania: Treatments Hub
• Liposomal Amphotericin B
• Miltefosine & Antimonials
• Prevention & Vector Control
• All Parasites
• Malaria
• Toxoplasma
• Trypanosoma (Sleeping Sickness)
• Acanthamoeba
• Infectious Disease
• Dermatology
• Immunology
• All Conditions

Back to Table of Contents

×

Featured Videos